REG - Oxford Nanopore Tech - Result of AGM

Oxford Nanopore TechnologiesAnnouncement

04/06/2026 14:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260604:nRSD0499Ha&default-theme=true

RNS Number : 0499H  Oxford Nanopore Technologies plc  04 June 2026

04 June 2026

Oxford Nanopore Technologies plc

(the "Company")

Results of Annual General Meeting

 

The Annual General Meeting of the Company was held earlier today. All
resolutions, as set out in the Company's Notice of Annual General Meeting
dated 1 May 2026, were passed by the appropriate majority on a
poll. Details of the poll results are set out below.

 

Oxford Nanopore Technologies plc Annual General Meeting Poll Results:

 

 

 No.    RESOLUTION                                                                     VOTES        %       VOTES       %      VOTES        % of ISC VOTED  VOTES

FOR
AGAINST
TOTAL
WITHHELD
 1.     To receive and consider the Directors' report, the Audited Statement of        644,479,235  99.99%  53,609      0.01%  644,532,844  66.25%          5,809,438
        Accounts and Auditor's Report of the Company for the financial year ended 31
        December 2025
 2.     To receive and approve the Directors' Remuneration Report for the year ended   635,703,914  98.61%  8,979,992   1.39%  644,683,906  66.26%          5,658,376
        31 December 2025
 3.     To elect Francis Van Parys as a director of the Company                        644,496,369  99.95%  346,047     0.05%  644,842,416  66.28%          5,499,866
 4.     To re-elect Dr Sarah Fortune as a director of the Company                      642,145,731  98.77%  8,001,129   1.23%  650,146,860  66.82%          195,422
 5.     To re-elect Adrian Hennah as a director of the Company                         641,793,032  98.72%  8,342,451   1.28%  650,135,483  66.82%          206,799
 6.     To re-elect Nicholas Keher as a director of the Company                        644,012,773  99.05%  6,193,516   0.95%  650,206,289  66.83%          135,993
 7.     To re-elect Dr Daniel Mahony as a director of the Company                      642,158,034  99.60%  2,599,012   0.40%  644,757,046  66.27%          5,585,236
 8.     To re-elect John O'Higgins as a director of the Company                        641,833,262  99.55%  2,923,769   0.45%  644,757,031  66.27%          5,585,251
 9.     To re-elect Dr Heather Preston as a director of the Company                    641,939,772  98.74%  8,206,188   1.26%  650,145,960  66.82%          196,322
 10.    To re-elect Katherine (Kate) Priestman as a director of the Company            642,128,939  98.77%  8,017,121   1.23%  650,146,060  66.82%          196,222
 11.    To re-elect Duncan Tatton-Brown as a director of the Company                   615,129,122  94.62%  34,986,815  5.38%  650,115,937  66.82%          226,345
 12.    To appoint Deloitte LLP as auditors of the Company                             638,710,166  99.10%  5,822,215   0.90%  644,532,381  66.25%          5,809,901
 13.    To authorise the Audit & Risk Committee to determine the remuneration of       639,055,685  99.11%  5,769,712   0.89%  644,825,397  66.28%          5,516,885
        the auditors
 14.    To authorise the board of directors to allot shares                            622,831,323  96.59%  21,984,854  3.41%  644,816,177  66.28%          5,526,105
 15.    To disapply pre-emption rights*                                                625,847,515  97.07%  18,881,645  2.93%  644,729,160  66.27%          5,613,122
 16.    To further disapply pre-emption rights*                                        620,910,261  96.31%  23,811,090  3.69%  644,721,351  66.27%          5,620,931
 17.    To authorise the Company to make market purchases*                             644,443,311  99.94%  368,535     0.06%  644,811,846  66.28%          5,530,436
 18.    To authorise the Company to hold any general meeting (other than an Annual     631,898,194  97.99%  12,938,231  2.01%  644,836,425  66.28%          5,505,857
        General Meeting) on not less than 14 clear days' notice*
 19.    To authorise UK political expenditure not exceeding £100,000                   642,283,505  99.77%  1,512,176   0.23%  643,795,681  66.17%          6,546,601

 

* Special Resolution

 

NOTES:

 

1.   Votes "For" and "Against" are expressed as a percentage of votes
received.

 

2.   The total number of ordinary shares in issue and eligible to be voted
on at the AGM was 972,930,353.

 

3.   A "Vote withheld" is not a vote in law and is not counted in the
calculation of the percentage of shares voted "For" or "Against" any
resolution nor in the calculation of the proportion of "Total issued share
capital voted" for any resolution.

 

4.   The Board appreciates the support shown by shareholders for the
resolutions at today's AGM.

 

In accordance with Listing Rule 9.6.2, a copy of the resolutions will shortly
be submitted to the National Storage Mechanism and will be available for
inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

 

A copy of the poll results for the AGM will also be available shortly on the
Company's website at
https://nanoporetech.com/about-us/investors/shareholder-information
(https://nanoporetech.com/about-us/investors/shareholder-information) .

 

 

-ENDS-

For further information please contact:

cosec@nanoporetech.com (mailto:cosec@nanoporetech.com)

ir@nanoporetech.com (mailto:ir@nanoporetech.com)

 

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society
through enabling the analysis of anything, by anyone, anywhere. The Group has
developed a new generation of nanopore-based sensing technology that is
currently used for real-time, high-performance, accessible, and scalable
analysis of DNA and RNA. The technology is used in more than 125 countries, to
understand the biology of humans, plants, animals, bacteria, viruses and
environments as well as to understand diseases such as cancer.  Oxford
Nanopore's technology also has the potential to provide broad, high impact,
rapid insights in a number of areas including healthcare, food and
agriculture. Oxford Nanopore Technologies products are for Research Use Only
(RUO). Products labelled/branded as Oxford Nanopore Diagnostics may be RUO or
may be regulated as in‐vitro diagnostic devices in some jurisdictions,
please check individual product labelling. For more information, please
visit: https://nanoporetech.com/ (https://nanoporetech.com/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGSSMFDLEMSESM



            Copyright 2019 Regulatory News Service, all rights reserved